Beneficial response to interleukin 1 receptor antagonist in traps [2]

American Journal of Medicine

Volumn 117, Issue 3, 2004, Pages 208-210

  Simon, Anna ^a   Bodar, Evelien J ^a   Van Der Hilst, Jeroen C H ^a   Van Der Meer, Jos W M ^a   Fiselier, Theo J W ^a   Cuppen, Marcel P J M ^b   Drenth, Joost P H ^c  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b SLINGELAND HOSPITAL   (Netherlands)

^c EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; ETANERCEPT; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; RAPAMYCIN; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TUMOR NECROSIS FACTOR RECEPTOR 1; ANTIRHEUMATIC AGENT; IL1RN PROTEIN, HUMAN; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1 RECEPTOR TYPE I; SIALOGLYCOPROTEIN; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; ANAMNESIS; CASE REPORT; CLINICAL FEATURE; DRUG HYPERSENSITIVITY; FEMALE; FEVER; GENE MUTATION; HUMAN; INFLAMMATION; LABORATORY TEST; LETTER; PAIN; PRIORITY JOURNAL; SKIN MANIFESTATION; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED PERIODIC SYNDROME; ANTAGONISTS AND INHIBITORS; FAMILIAL MEDITERRANEAN FEVER; GENETICS;

ADULT; ANTIRHEUMATIC AGENTS; FAMILIAL MEDITERRANEAN FEVER; FEMALE; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; RECEPTORS, INTERLEUKIN-1; RECEPTORS, INTERLEUKIN-1 TYPE I; RECEPTORS, TUMOR NECROSIS FACTOR; SIALOGLYCOPROTEINS;

EID: 3843110981     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2004.02.039     Document Type: Letter

References (10)

1. J.J. Chae, H.D. Komarow, and J. Cheng Targeted disruption of pyrin, the FMF protein, causes heightened sensitivity to en Mol Cell 11 2003 591 604
2. J. Frenkel, G.T. Rijkers, and S.H. Mandey Lack of isoprenoid products raises ex vivo interleukin-1beta secretion in hyperimmunoglobulinemia D and periodic fever syndrome Arthritis Rheum 46 2002 2794 2803
3. I. Aksentijevich, M. Nowak, and M. Mallah De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): A new member of the expanding family of pyrin-associated autoinflammatory diseases Arthritis Rheum 46 2002 3340 3348
4. G. Nuki, B. Bresnihan, M.B. Bear, D. McCabe Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomized, double-blind, placebo-controlled trial Arthritis Rheum 46 2002 2838 2846
5. P.N. Hawkins, H.J. Lachmann, M.F. McDermott Interleukin-1-receptor antagonist in the Muckle-Wells syndrome N Engl J Med 348 2003 2583 2584
6. E. Drewe, E.M. McDermott, and P.T. Powell Prospective study of anti-tumour necrosis factor receptor superfamily 1B fusion protein, and case study of anti-tumour necrosis factor receptor superfamily 1A fusion protein, in tumour necrosis factor receptor associated periodic syndrome (TRAPS): clinical and laboratory findings in a series of seven patients Rheumatology (Oxford) 42 2003 235 239
7. E. Drewe, R.J. Powell Novel treatment for tumour necrosis factor receptor associated periodic syndrome (TRAPS): case history of experience with infliximab and sirolimus post etanercept Clin Exp Rheumatol 20 suppl. 26 2002 S71 (abstract)
8. K.M. Hull, E. Drewe, and I. Aksentijevich The TNF receptor-associated periodic syndrome (TRAPS): emerging concepts of an autoinflammatory disorder Medicine (Baltimore) 81 2002 349 368
9. A. Simon, M. van Deuren, and P.J. Tighe Genetic analysis as a valuable key to diagnosis and treatment of periodic Fever Arch Intern Med 161 2001 2491 2493
10. R.M. Fleischmann Addressing the safety of anakinra in patients with rheumatoid arthritis Rheumatology (Oxford) 42 Suppl 2 2003 ii29 ii35